At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LBPH Longboard Pharmaceuticals, Inc.
Market Closed 09-27 16:00:00 EDT
32.00
+0.80
+2.56%
盘后32.00
+0.000.00%
19:47 EDT
High32.21Low30.70Vol279.05K
Open31.37D1 Closing31.20Amplitude4.84%
Mkt Cap1.24BTradable Cap794.27MTotal Shares38.90M
T/O8.88MT/O Rate1.12%Tradable Shares24.82M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Longboard Pharmaceuticals Initiates Phase 3 Deep Sea Study Evaluating Bexicaserin In Dravet Syndrome
Reuters  ·  09-26 20:44
BRIEF-Longboard Pharmaceuticals Initiates Phase 3 Deep Sea Study Evaluating Bexicaserin In Dravet Syndrome
Longboard Pharmaceuticals Initiates Phase 3 Deep Sea Study Evaluating Bexicaserin in Dravet Syndrome
THOMSON REUTERS  ·  09-26 20:30
Longboard Pharmaceuticals Initiates Phase 3 Deep Sea Study Evaluating Bexicaserin in Dravet Syndrome
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Business Wire  ·  09-26 20:30
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Zacks  ·  09-21
Longboard Stock Soars on FDA Designations for Epilepsy Drug
Longboard Pharma gains on FDA designations for lead asset
seekingalpha  ·  09-19
Longboard Pharma gains on FDA designations for lead asset
Longboard Pharmaceuticals Shares Rise on FDA's Designations For Dravet Syndrome Treatment
Dow Jones  ·  09-19
Longboard Pharmaceuticals Shares Rise on FDA's Designations For Dravet Syndrome Treatment
Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA
MT Newswires Live  ·  09-19
Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (Lp352) in Dravet Syndrome
THOMSON REUTERS  ·  09-19
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (Lp352) in Dravet Syndrome
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
Business Wire  ·  09-19
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
Longboard Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $80 From $60
THOMSON REUTERS  ·  09-18
Longboard Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $80 From $60
Longboard Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones  ·  09-17
Longboard Pharmaceuticals Is Maintained at Outperform by Wedbush
Wedbush Sticks to Their Buy Rating for Longboard Pharmaceuticals (LBPH)
TIPRANKS  ·  09-17
Wedbush Sticks to Their Buy Rating for Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals Inc : Wedbush Raises Target Price to $44 From $40
THOMSON REUTERS  ·  09-17
Longboard Pharmaceuticals Inc : Wedbush Raises Target Price to $44 From $40
Wedbush Raises Price Target on Longboard Pharmaceuticals to $44 From $40, Keeps Outperform Rating
MT Newswires Live  ·  09-17
Wedbush Raises Price Target on Longboard Pharmaceuticals to $44 From $40, Keeps Outperform Rating
Truist Financial Sticks to Its Buy Rating for Longboard Pharmaceuticals (LBPH)
TIPRANKS  ·  09-17
Truist Financial Sticks to Its Buy Rating for Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Dow Jones  ·  09-17
Longboard Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Longboard Pharmaceuticals Initiated at Buy by Truist Securities
Dow Jones  ·  09-10
Longboard Pharmaceuticals Initiated at Buy by Truist Securities
Buy Recommendation: Longboard Pharmaceuticals’ Market Growth Potential with Bexicaserin in the Epilepsy Sector
TIPRANKS  ·  09-10
Buy Recommendation: Longboard Pharmaceuticals’ Market Growth Potential with Bexicaserin in the Epilepsy Sector
Truist Initiates Longboard Pharmaceuticals at Buy With $60 Price Target
MT Newswires Live  ·  09-10
Truist Initiates Longboard Pharmaceuticals at Buy With $60 Price Target
Truist Initiates Longboard Pharmaceuticals at Buy With $60 Price Target
MT Newswires Live  ·  09-10
Truist Initiates Longboard Pharmaceuticals at Buy With $60 Price Target

Introduction

Company Name.
Longboard Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Issue price:
--